Scientists at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) have made one of the most ...

Akeega – which combines the active ingredients in J&J's PARP inhibitor Zejula (niraparib) and androgen blocker Zytiga ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC) ...

Dr Moore stated: “PARP inhibitors are the first truly targeted therapy to benefit patients with ovarian cancer...transformative in a biomarker selected way” and noted: “Best place to use ...

PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.

Results from the PAOLA-1 study showed that the PARP inhibitor drug significantly increased the time women lived without disease progression when added to the standard-of-care, Genentech’s ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Zejula with Zytiga and prednisone delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer ...

Mr. Høiland is already well-acquainted with Allarity's mission and operations, having served as a strategic consultant to the ...

spoke with Healio about developments in PARP inhibitors for ovarian cancer, unmet needs among patients with ovarian cancer and continuing momentum in drug development and immunotherapy.